It's now four months since patient six was dosed. So SVR12, if it has in fact happened, is not the criteria for a price sensitive announcement. I actually fully agree with their reporting structure. Wait for the DSMB report of all three in this cohort. Maybe they can squeeze it in before the year is out??
